PEDIATRICS Vol. 76 No. 3 September 1985, pp. 361-364
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilson, D. M.
Right arrow Articles by Rosenfeld, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilson, D. M.
Right arrow Articles by Rosenfeld, R. G.

Subcutaneous Versus Intramuscular Growth Hormone Therapy: Growth and Acute Somatomedin Response

Darrell M. Wilson MD1, Bonita Baker BS1, Raymond L. Hintz MD1, and Ron G. Rosenfeld MD1

1 Department of Pediatrics, Stanford University Medical Center, Stanford, California

To determine the optimal route of growth hormone administration, a comparison was made of the acute somatomedin response and chronic growth response to either intramuscular or subcutaneous growth hormone in 20 children with growth hormone deficiency. None of the children had received growth hormone for at least 2 weeks prior to their random selection to receive growth hormone by either the subcutaneous (N = 11) or intramuscular (N = 9) route. Plasma samples for determination of levels of insulin-like growth factors I and II (IGF-I and IGF-II) were obtained prior to therapy and 20 hours after the first and fourth of four daily injections of growth hormone. Growth rate and growth hormone antibody levels were determined before and after 6 months of therapy. IGF-I levels tripled in both treatment groups after four days of growth hormone injections, whereas IGF-II levels nearly doubled, with no significant difference between the intramuscular or subcutaneous group. After 6 months of therapy, there was no significant difference in growth rate and only two patients had developed growth hormone antibodies. Both patients and parents expressed a preference for the subcutaneous method. The identical rises in the IGF-I and IGF-II levels following a brief course of either subcutaneous or intramuscular injections of growth hormone, the similar growth rates, the low incidence of antibody development, and the preference for the subcutaneous route all suggest that the subcutaneous route is the method of choice for chronic growth hormone therapy.

Key Words: growth hormone • somatomedin • insulin-like growth factor I • insulin-like growth factor II • growth

Submitted on July 20, 1984
Accepted on October 4, 1984